UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1367-4
Program Prior Authorization/Notification
Medication Bylvay™ (odevixibat)
P&T Approval Date 9/2021, 9/2022, 8/2023, 8/2024
Effective Date 11/1/2024
1. Background:
Bylvay (odevixibat) is an ileal bile acid transporter inhibitor indicated for the treatment of
pruritis in patients aged 3 months or older with progressive familial intrahepatic cholestasis
(PFIC). Bylvay is also indicated for the treatment of pruritis in patients 12 months of age and
older with Alagille syndrome (ALGS).
Limitation of Use:
Bylvay may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11
variants resulting in non-functional or complete absence of bile salt export pump protein (BSEP-
3).
2. Coverage Criteriaa:
A. Progressive Familial Intrahepatic Cholestasis
1. Initial Authorization
a. Bylvay will be approved based upon both of the following criteria:
(1) Diagnosis of progressive familial intrahepatic cholestasis (PFIC)
-AND-
(2) Patient is experiencing pruritus associated with PFIC.
Authorization will be issued for 12 months.
2. Reauthorization
a. Bylvay will be approved based on the following criterion:
(1) Documentation of positive clinical response to Bylvay therapy
Authorization will be issued for 12 months.
B. Alagille Syndrome
1. Initial Authorization
a. Bylvay will be approved based upon both of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
1
(1) Diagnosis of Alagille syndrome (ALGS).
-AND-
(2) Patient is experiencing pruritus associated with ALGS.
Authorization will be issued for 12 months.
2. Reauthorization
a. Bylvay will be approved based on the following criterion:
(1) Documentation of positive clinical response to Bylvay therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Bylvay™ [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; February 2024.
Program Prior Authorization/Notification - Bylvay™ (odevixibat) Notification
Change Control
9/2021 New program
9/2022 Annual review with no changes to criteria. Added state mandate
footnote.
8/2023 Added coverage criteria for new ALGS indication. Updated reference.
8/2024 Annual review. Updated initial authorization durations to 12 months.
Updated background and reference.
© 2024 UnitedHealthcare Services, Inc.
2